Revolution Medicines' Rasonge receives second-line pancreatic cancer nod, could drive $2.3B sales by 2028

Revolution Medicines announced that its RAS inhibitor Rasonge earned a second-line indication for pancreatic ductal adenocarcinoma, marking the first regulatory step in the company's PDAC strategy.

Analysts at Truist Securities highlighted the drug's unprecedented survival benefit and said the approval creates a commercial foundation for future expansion into first-line PDAC treatment.

Truist projects that if Rasonge moves into the first-line setting and expands to other cancers such as non‑small cell lung cancer and colorectal cancer, revenue could reach $2.3 billion by 2028.

The firm’s analysts described Revolution Medicines as poised to become the next oncology titan based on this development.